Please assess the completion status of the following clinical trial:

Trial Title: Young Blind Child Melatonin Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1-20 years~* Blindness for the past year (verified by an ophthalmologic exam), but otherwise in general good health.~Exclusion Criteria:~* Abnormal heart, lung, kidney, liver disease or a primary sleep disorder,~* Significant clinical abnormalities (other than blindness),~* Use of medications with known effects on melatonin metabolism (e.g. beta-adrenergic blocking drugs or tricyclic antidepressants).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).